Last reviewed · How we verify

Denver Infectious Disease Consultants, PLLC — Portfolio Competitive Intelligence Brief

Denver Infectious Disease Consultants, PLLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Raltegravir and Abacavir/Lamivudine Raltegravir and Abacavir/Lamivudine marketed Antiretroviral combination (INSTI + NRTI) HIV integrase, HIV reverse transcriptase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Charlotte-Paige Rolle, MD · 1 shared drug class
  2. Fundacion SEIMC-GESIDA · 1 shared drug class
  3. Fundação Bahiana de Infectologia · 1 shared drug class
  4. Hospitales Universitarios Virgen del Rocío · 1 shared drug class
  5. Saint Michael's Medical Center · 1 shared drug class
  6. The University of Texas Health Science Center, Houston · 1 shared drug class
  7. ViiV Healthcare · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Denver Infectious Disease Consultants, PLLC:

Cite this brief

Drug Landscape (2026). Denver Infectious Disease Consultants, PLLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/denver-infectious-disease-consultants-pllc. Accessed 2026-05-17.

Related